Zhejiang Medicine Hits Day High with 7.86% Surge in Stock Price

Zhejiang Medicine Co., Ltd. has experienced a significant uptick in its stock performance, gaining 7.86% on March 6, 2026. The stock reached an intraday high of CNY 18.54, reflecting a strong day of trading activity. This performance stands in contrast to the China Shanghai Composite, which saw a modest increase of 0.38% on the same day. Over the past week, Zhejiang Medicine has shown a robust 12.83% increase, while its monthly performance has surged by 17.82%. Year-to-date, the stock has risen by 32.61%, significantly outperforming the broader market index, which has only gained 3.91% in the same timeframe. Financially, the company has reported positive results for the last four consecutive quarters, with operating cash flow reaching a high of CNY 2,018.84 million. The company maintains a strong cash position, with cash and equivalents totaling CNY 6,124.58 million. Despite a lower return on equity of 10.20% compared to the industry average, Zhejiang Medicine's valuation remains attractive with a price-to-book ratio of 1.39. Overall, the stock's recent performance highlights its resilience in the pharmaceuticals and biotechnology sector.